Urology
Volume 71, Issue 1 , Pages 156-160 , January 2008

Etodolac, a Selective Cyclooxygenase-2 Inhibitor, Induces Upregulation of E-Cadherin and Has Antitumor Effect on Human Bladder Cancer Cells In Vitro and In Vivo

  • Asako Okamoto

      Affiliations

    • International Center for Medical Research and Treatment, Kobe University School of Medicine, Kobe, Japan
    • ,
  • Toshiro Shirakawa

      Affiliations

    • International Center for Medical Research and Treatment, Kobe University School of Medicine, Kobe, Japan
    • Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • Corresponding Author InformationReprint requests: Toshiro Shirakawa, M.D., Ph.D., International Center for Medical Research and Treatment, Kobe University School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017 Japan.
    • ,
  • Toshinori Bito

      Affiliations

    • Division of Dermatology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Katsumi Shigemura

      Affiliations

    • Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Katsuyuki Hamada

      Affiliations

    • Department of Obstetrics and Gynecology, Ehime University School of Medicine, Ehime, Japan
    • ,
  • Akinobu Gotoh

      Affiliations

    • Laboratory of Cell and Gene Therapy, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan
    • ,
  • Masato Fujisawa

      Affiliations

    • Division of Urology, Department of Organs Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
    • ,
  • Masato Kawabata

      Affiliations

    • International Center for Medical Research and Treatment, Kobe University School of Medicine, Kobe, Japan

Received 15 May 2007 ,Accepted 26 September 2007.

References 

  1. Boring CC, Squires TS, Tong T, et al. Cancer statistics, 1994. CA Cancer J Clin. 1994;44:7–26
  2. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am. 2003;30:765–776
  3. National Cancer Institute: Fact sheet chemoprevention. http://www.med.uni-bonn.de/Cancernet/600042.html accessed May 15, 2007.
  4. Leppert JT, Shvarts O, Kawaoka K, et al. Prevention of bladder cancer: a review. Eur Urol. 2006;49:226–234
  5. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000;82:1364–1369
  6. Pruthi R, Derksen E, Gaston K, et al. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology. 2004;64:637–642
  7. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157–33160
  8. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA. 1996;93:4816–4820
  9. Mohammed SI, Dhawan D, Abraham S, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther. 2006;5:329–336
  10. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8:97–114
  11. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000;30:3–21
  12. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993;24:105–110
  13. Shariat SF, Kim JH, Ayala GE, et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003;169:938–942
  14. Shigemura K, Shirakawa T, Wada Y, et al. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology. 2005;66:1239–1244
  15. Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001;57:60–65
  16. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  17. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190:279–286
  18. Bubenik J, Baresova M, Viklicky V, et al. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 1973;11:765–773
  19. Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr. 1978;49:5–9
  20. Kotoh S, Naito S, Yokomizo A, et al. Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol. 1997;157:1054–1058
  21. Guo JY, Huo HR, Zhao BS, et al. Cinnamaldehyde reduces IL-1beta-induced cyclooxygenase-2 activity in rat cerebral microvascular endothelial cells. Eur J Pharmacol. 2006;537:174–180
  22. Shirakawa T, Hamada K, Zhang Z, et al. A COX-2 promoter-based replication-selective adenoviral vector to target the COX-2-expressing human bladder cancer cells. Clin Cancer Res. 2004;10:4342–4348
  23. Bito T, Roy S, Sen CK, et al. Flavonoids differentially regulate IFN gamma-induced ICAM-1 expression in human keratinocytes: molecular mechanisms of action. FEBS Lett. 2002;520:145–152
  24. Komhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol. 2000;157:29–35
  25. Wild PJ, Kunz-Schughart LA, Stoehr R, et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol. 2005;27:385–391
  26. Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 1993;53:3241–3245
  27. Syrigos KN, Krausz T, Waxman J, et al. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer. 1995;64:367–370
  28. Shariat SF, Matsumoto K, Kim J, et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003;170:985–989
  29. Noda M, Tatsumi Y, Tomizawa M, et al. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines. J Gastroenterol. 2002;37:896–904
  30. Lin S, Levin L, Emodi O, et al. Etodolac versus dexamethasone effect in reduction of postoperative symptoms following surgical endodontic treatment: a double-blind study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:814–817

PII: S0090-4295(07)02195-4

doi: 10.1016/j.urology.2007.09.061

Urology
Volume 71, Issue 1 , Pages 156-160 , January 2008

Article Tools

* Image Usage & Resolution